Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 4/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.45 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28044374 | 0.89 | PIM1 (0.56) | FLT3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL6479262 | 0.86 | PIM1 (0.53) | FLT3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL24138802 | 0.84 | NPC1 (0.48) | FLT3NPC1RAB9ASMN1; SMN2ITGB3 | |
| SCHEMBL6478966 | 0.84 | SMN1; SMN2 (0.51) | FLT3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL6479111 | 0.80 | PSMB8 (0.51) | FLT3NPC1RAB9ASMN1; SMN2TP53 | |
| Isophthalic Acid SCHEMBL27887534 | 0.80 | NPC1 (0.64) | FLT3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL28125380 | 0.80 | KDM4E (0.46) | FLT3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL8716521 | 0.79 | PRMT1 (0.59) | PIM1CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| Hydrochloric Acid SCHEMBL8713031 | 0.78 | PRMT1 (0.58) | PIM1CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL10510996 | 0.78 | FLT3 (0.76) | FLT3NPC1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894042-B2 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1476448-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040224976-A1 | Azabicyclic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | disclosed |
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003070731-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | FLT3 824/4885NPC1 284/4885RAB9A 1279/4885 |
| US-20040224976-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | FLT3 824/4885NPC1 284/4885RAB9A 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.